CMS grants pass-through payment status for Heron's APONVIE effective April 1, 2023

HERON THERAPEUTICS, INC. /DE/

CMS approves three-year transitional pass-through status for APONVIE under C-code C9145 starting April 1, 2023.
APONVIE will be reimbursed separately outside surgical bundle at ASP+6% in HOPD and ASC settings.
APONVIE is the only PONV drug with Medicare reimbursement in both outpatient settings; launched March 6, 2023.
Over 70% of surgery opportunity is in outpatient settings; CEO says status facilitates patient access and billing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.